Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | COMT | P21964 | 2/20 | 0.93 |
| ▸ | MMP2 | P08253 | 1/20 | 0.93 |
| ▸ | MMP9 | P14780 | 1/20 | 0.93 |
| ▸ | MMP8 | P22894 | 1/20 | 0.93 |
| ▸ | MMP13 | P45452 | 1/20 | 0.93 |
| ▸ | TP53 | P04637 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578829 | 1.00 | MAPT (1.00) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL2250333 | 0.96 | COMT (1.00) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL17498803 | 0.95 | MAPT (0.91) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL12113071 | 0.94 | MAPT (0.89) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL20512985 | 0.93 | MAPT (0.87) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL17498773 | 0.92 | MAPT (0.85) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL19507467 | 0.89 | KDM4E (0.84) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL16147976 | 0.88 | MAPT (0.78) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL12351223 | 0.87 | COMT (0.79) | MAPTKMT2AMEN1KDM4EPOLB | |
| SCHEMBL17705602 | 0.87 | MMP2 (0.80) | MAPTKMT2AMEN1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337018-A1 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2015-11-26 | — | — | US | claimed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | claimed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | claimed |
| EP-2567225-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | Virginia Tech Intellectual Properties, Inc. (US) | 2013-03-13 | — | — | EP | claimed |
| WO-2011140215-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | WO | claimed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | claimed |
| US-11529354-B2 | Methods and compositions for the treatment of tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529354-B2 | Methods and compositions for the treatment of tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210137932-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210137932-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-13 | — | — | US | disclosed |
| EP-2567225-B1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-2567225-B1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | BOISE STATE UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-9101573-B2 | Lanthionine synthetase component C-like proteins as molecular targets for preventing and treating diseases and disorders | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2897632-A2 | COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS | Universidad Andres Bello (CL) | 2015-07-29 | — | — | EP | disclosed |
| WO-2013179264-A2 | USE OF COMPOUNDS THAT SELECTIVELY MODULATE ASTROCYTIC RELEASE OF SUBSTANCES THROUGH HEMICHANNELS OF CONNEXINS AND PANNEXINS, WITHOUT INFLUENCING GAP JUNCTIONS, FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | UNIVERSIDAD ANDRES BELLO (CL) | 2013-12-05 | — | — | WO | disclosed |
| EP-2567225-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | Virginia Tech Intellectual Properties, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140215-A2 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10286070-B2 | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders | IL6, OGFRL1, OGFR | MAPT 2503/4885KMT2A 1658/4885MEN1 2377/4885 |
| US-20110275558-A1 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS | LANCL2, ACSL1, LANCL1 | MAPT 4166/4885KMT2A 4112/4885MEN1 4389/4885 |
| US-11529354-B2 | Methods and compositions for the treatment of tuberculosis | IFNG, FNTB, TYMS | MAPT 1469/4885KMT2A 4328/4885MEN1 3654/4885 |
| US-20210137932-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS | IFNG, FNTB, TYMS | MAPT 1469/4885KMT2A 4328/4885MEN1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.